How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Document

    Do you agree NICE should focus on guidance production and maintenance on priority areas (section 5) and these should be reviewed periodically to ensure NICE is supporting what the health and care system needs? If you disagree, please give reason and rationale.

  • Question on Document

    Do you agree that NICE should be transparent about its remit (section 3.12, section 6.1.1 and 6.2)? If you disagree, please give reason and rationale.

  • Question on Document

    Do you think the new process and consideration factors for NICE to propose topics to the Secretary of State for NHAP are robust and transparent (section 4 and Annex A)? If you disagree, please give reason and rationale. Are there any other factors NICE should include to consider?

  • Question on Document

    Do you think the new merged single-stage prioritisation framework is more streamlined and efficient for topic selection? If you disagree, please give reason and rationale.

NICE-wide topic prioritisation: the manual

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

14 Tell NICE about a topic

There will be a common proforma for topic suggestions, with a single letterbox or email: topics@nice.org.uk.

Additionally, information about topics can be provided directly to:

  • NICE's interventional procedures notification page (for interventional procedures)

  • UK PharmaScan (for medicines)

  • NHS Innovation Service (for devices, diagnostics and digital health technologies).

  • NICE Advice can help inform market access strategies for all types of technology. They can provide help to understand the healthcare landscape, identify the most appropriate route to NHS access, and explore the value of the technology with system stakeholders.

  • NICE Advice can also help companies develop evidence that demonstrates the clinical and cost effectiveness of all types of technology. They provide feedback on evidence generation plans, and help companies understand health technology assessment and the perspective of decision makers. NICE Advice also provides a comprehensive peer review service for economic models that helps companies optimise the model's structure, computation, coding, usability and transparency.

  • For medicines that have been selected for NICE guidance, the NICE commercial and managed access teams can arrange discussions between NICE, NHS England (NHSE) and companies. This supports timely discussions to address issues of value, affordability and transactability, as appropriate, to give patients the fastest possible access to clinically and cost-effective treatments. Companies can email NICE's Commercial Liaison Team (CLPT@nice.org.uk; which includes NICE's Patient Access Schemes Liaison Unit [PASLU]). The Commercial Liaison Team will then arrange discussions with the Managed Access Team at NICE or the NHSE Commercial Medicines Directorate, or both, as necessary.